Home › Non-Small Cell Lung Cancer › Florida › Tampa
Non-Small Cell Lung Cancer clinical trials in Tampa, FL
51 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Tampa (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 2/3
- Moffitt Cancer Center /ID# 276785, Tampa
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Moffitt Cancer Center, Tampa
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #8, Tampa
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Moffitt Cancer Center-International Plaza, Tampa
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- and 1 more
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPhase 1
- Moffitt Cancer Center, Tampa
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
RecruitingPhase 2
- Moffit Cancer Centre, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RecruitingPhase 1
- ALX Center 7, Tampa
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
RecruitingPhase 3
- H Lee Moffitt Cancer Center and Research Institute, Tampa
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- Moffitt Cancer Center, Tampa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Florida Cancer Specialists, Tampa
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecruitingPhase 3
- Moffitt Cancer Center, Tampa
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RecruitingPhase 3
- H. Lee Moffitt Cancer Center & Research Institute, Tampa
- Local Institution - 0647, Tampa
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RecruitingPhase 2/3
- H. Lee Moffit Cancer center and research institute, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RecruitingPhase 1
- Moffitt Cancer Center, Tampa
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
RecruitingPhase 1
- Moffitt Cancer Center, Tampa
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RecruitingPhase 2/3
- James A. Haley Veterans Hospital, Tampa
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RecruitingPhase 1/2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Tampa
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- Moffitt Cancer Center, Tampa
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RecruitingPhase 2
- Moffitt Cancer Center and Research Institute, Tampa
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
RecruitingPhase 3
- Moffitt Cancer Center, Tampa
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 1/2
- Moffit Cancer Center, Tampa
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
RecruitingPhase 3
- Moffit Cancer Center, Tampa
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecruitingPhase 1/2
- H Lee Moffitt Cancer Center and Research Institute, Tampa
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 2
- H Lee Moffitt Cancer Center and Research Institute, Tampa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecruitingPhase 3
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
RecruitingPhase 1
- Moffitt Cancer Center, Tampa
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RecruitingPhase 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- Lee Moffitt Cancer Center, Tampa
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RecruitingPhase 1
- Moffitt Cancer Center, Tampa
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Moffitt Cancer Center, Tampa
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
RecruitingPhase 2
- Moffit Cancer Center, Tampa
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Tampa
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RecruitingPhase 1/2
- Moffitt Cancer Center, Tampa
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Tampa
- Breast Cancer43 studies
- Cancer (all types)39 studies
- Colorectal Cancer34 studies
- Acute Myeloid Leukemia29 studies
- Metastatic Cancer29 studies
- Lung Cancer29 studies
- Pancreatic Cancer26 studies
- Ovarian Cancer21 studies
- Melanoma19 studies
- Myelodysplastic Syndromes19 studies
- Prostate Cancer18 studies
- Heart Failure18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.